جست‌وجوی استاد و پژوهشگر

• Statistical Machine Learning
• Bayesian Experimental Design
• Probabilistic Programming
• +۳ مورد دیگر

Tom Rainforth is an Associate Professor of Statistical Machine Learning at the University of Oxford's Department of Statistics, leading the RainML Research Lab (rainml.uk). He holds a Tutorial Fellowship at Mansfield College and is Principal Investigator of the ERC Starting Grant 'Data-Driven Algorithms for Data Acquisition' (2024–2029). Previously, he held roles including a postdoc under Yee Whye Teh (2017–2019), Junior Research Fellow at Christ Church College (2019–2019), and Florence Nightingale Bicentennial Fellow (2020–2024). He earned his MEng in Mechanical Engineering from the University of Cambridge and his D.Phil from Oxford under Frank Wood and Michael Osborne, focusing on probabilistic programming and Monte Carlo methods. He briefly worked in Ferrari's Formula 1 team. Research Interests : Bayesian experimental design, probabilistic and data-efficient machine learning, active learning, deep learning (with a focus on probabilistic approaches), probabilistic programming, and Monte Carlo methods. His work emphasizes statistical efficiency and adaptive algorithms. Publications : Recent contributions span modern Bayesian experimental design, adaptive importance sampling (Daisee), and applications of probabilistic methods in LLMs and generative models. His research bridges theory and practice, addressing challenges in scalability and robustness. Awards : ERC Starting Grant (2024–2029), highlighting his leadership in foundational AI research. Advising & Grants : Supervises 15 graduate students, including work on Bayesian neural networks, generative flows, and experimental design. His ERC grant supports cutting-edge data-driven algorithm development. Labs & Teams : Directs the RainML Lab, which develops scalable Bayesian methods and probabilistic AI systems.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +۷ مورد دیگر

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Vikramaditya G. Yadavمشاهده پروفایل

دانشیار

• Biocatalysis
• Bioremediation
• Bioprocess engineering
• +۱۵ مورد دیگر

Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.

Aberham Hailu Feyissaمشاهده پروفایل

دانشیار

• Food Process Engineering
• Heat and Mass Transfer
• Transport Phenomena in Porous Media
• +۷ مورد دیگر

Aberham Hailu Feyissa is an Associate Professor at the National Food Institute of the Technical University of Denmark , specializing in process modeling and sustainable food engineering. His research bridges complex transport phenomena with practical food manufacturing challenges. Ph.D. in Food Process Engineering, Technical University of Denmark MSc in Food Science, K.U.Leuven and Universiteit Gent BSc in Chemical Engineering, Bahir Dar University His work focuses on coupled mass and heat transfer during solid food processing, aiming to develop robust first-principles models for predictive process optimization. Key applications include Ohmic heating , digital twin technology , and bioactive ingredient extraction . Recent publications highlight his contributions to sustainable food processes , including insect-based feed modeling , seaweed bread kinetics , and clean-label cheese formulation . His methodological innovations span FTIR spectroscopy , computational fluid dynamics , and kinetic modeling . Supervisor for PhD students S. S. Turgut , M. E. Jabali , and Dahal S. Principal Investigator for projects like Modelling and Digitalisation of Food Processes and Sustainable Extraction of Bioactive Insect Fractions Active in conference presentations and peer review , he drives advancements in food process understanding through mechanistic modeling and mathematical simulation .

Wengong Jinمشاهده پروفایل

استادیار

• AI for drug discovery
• Generative AI models
• Geometric deep learning
• +۵ مورد دیگر

Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.

• Natural Products Chemistry
• Medicinal Chemistry
• Biosynthesis
• +۴ مورد دیگر

David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.

Thibault Mayorمشاهده پروفایل

استاد

• Protein Homeostasis
• Ubiquitin Proteasome System
• Neurodegenerative Diseases
• +۷ مورد دیگر

Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.

Shasha Chongمشاهده پروفایل

استادیار

• Transcriptional Regulation
• Intrinsically Disordered Proteins
• Single-Molecule Biophysics
• +۴ مورد دیگر

Shasha Chong is an Assistant Professor of Chemistry at the California Institute of Technology and a Ronald and JoAnne Willens Scholar. She earned her B.S. from the University of Science & Technology of China (2008) and Ph.D. from Harvard University (2014). Her research bridges chemistry, physics, and biology to investigate the molecular mechanisms of cellular processes, focusing on intrinsically disordered regions (IDRs) in transcription proteins. Research Focus: IDRs in transcriptional regulation, cancer biology, liquid-liquid phase separation, and single-molecule imaging techniques. Grants & Awards: CCE Innovation Award (2024), ALSF Innovation Grant, Mallinckrodt Research Grant, Margaret E. Early Medical Research Trust Grant. Collaborations: Caltech-City of Hope Biomedical Research Initiative Grant (2025). Teaching: Co-instructor for courses like Biochemistry Laboratory (Ch 11) and Advanced Topics in Biochemistry (BMB/Bi/Ch 174). Labs & Teams: Leads the Chong Laboratory at Caltech, focusing on interdisciplinary approaches combining single-molecule imaging, genome editing, and bioinformatics.

Weiping Tangمشاهده پروفایل

استاد

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +۵ مورد دیگر

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

Vadim Cherezovمشاهده پروفایل

استاد

• Membrane Protein Structure and Function
• G Protein-Coupled Receptors (GPCRs)
• Lipid-Protein Interactions
• +۳ مورد دیگر

Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.

Knut Reinertمشاهده پروفایل

استاد

• Algorithmic Bioinformatics
• Genomic Sequence Analysis
• Proteomics
• +۷ مورد دیگر

Professor Knut Reinert is a leading figure in algorithmic bioinformatics at the Free University of Berlin, where he holds a professorship in the Department of Mathematics and Computer Science. He also maintains a significant affiliation with the Max Planck Institute for Molecular Genetics in Berlin, where he leads the Efficient Algorithms for Omics Data group. His research spans both institutions through the Reinert Lab, which focuses on developing novel computational approaches for biological data analysis. Reinert's educational background includes a Diploma in Computer Science (1994) and a Doctorate (Dr. Ing./Ph.D., 1999, with honors) from the Max-Planck-Institut for Computer Science and Universität des Saarlandes in Saarbrücken. Prior to his professorship, he worked as a computer scientist under Prof. Gene Myers at Celera Genomics in Rockville, USA (1999-2002). His primary research interests center on algorithmic bioinformatics with specific focus on developing novel algorithms and data structures for biomedical mass data analysis. This includes creating mathematical models for genomic sequence analysis and algorithms for mass spectrometry data to detect differential protein expression between normal and diseased samples. His work bridges the gap between computational tool development and practical biological applications, with particular emphasis on NGS and proteomics data. The publications and projects led by Prof. Reinert demonstrate a consistent focus on advancing computational methods in bioinformatics. His research spans genomic sequence analysis, RNA research (particularly long non-coding RNAs), parallel computing applications, and GPU acceleration for biological data processing. The work shows increasing sophistication in handling large-scale biological datasets through innovative algorithmic approaches. Intel® Parallel Computing Center designation for his lab CUDA Research Center status DFG funding of 530 thousand Euros for RNA research de.NBI funding of 2 million Euros BMBF funded projects 'LIVE-DREAM' and 'EssBar' Prof. Reinert leads multiple significant research projects and has established strong collaborations with international partners including Texas A&M, Kings College London, Eberhardt-Karls Universität Tübingen, Robert-Koch-Institute, and various Turkish institutions. His lab receives funding from major organizations including DFG, BMBF, and Intel. The Reinert Lab maintains active teaching responsibilities at FU Berlin, offering courses at BSc, MSc, and PhD levels using both traditional and innovative learning concepts like e-learning and inverted classrooms. The Reinert Lab consists of two interconnected research groups that work closely with experimental biologists and medical researchers to develop practical computational solutions for real-world biological problems. The lab has established itself as a key player in the German and international bioinformatics community through its development of the widely-used SeqAn library and participation in national infrastructure initiatives.

Steven G. Clarkeمشاهده پروفایل

استاد

• Biochemistry
• Systems Biology
• Biological Regulation
• +۸ مورد دیگر

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

Kelly Arnoldمشاهده پروفایل

دانشیار

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +۵ مورد دیگر

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

David S. Eisenbergمشاهده پروفایل

استاد

• Protein Aggregation
• Amyloid Structures
• Prion Diseases
• +۵ مورد دیگر

David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.

Chang-Jun Liuمشاهده پروفایل

استاد مدعو

• Phenylpropanoid biosynthesis
• Lignin biosynthesis and modification
• Plant cell wall structure
• +۷ مورد دیگر

Chang-Jun Liu is a Senior Scientist in the Plant Science Group of the Biology Department at Brookhaven National Laboratory, where he has conducted research on plant phenylpropanoid biosynthesis and lignin metabolism since joining in 2005. He also holds an Adjunct Professor position in the Biochemistry & Cell Biology Department at Stony Brook University and serves as Associate Editor for Plant Cell & Environment (2024-present) and Frontiers in Plant Sciences (2015-present). Dr. Liu's educational background includes: Ph.D. in Plant Biochemistry and Molecular Biology from the Shanghai Institute of Plant Physiology, Chinese Academy of Science (1999) Dr. Liu's research integrates approaches from biochemistry, molecular genetics, biophysics, protein engineering, metabolic engineering, and synthetic biology to investigate phenylpropanoid and lignin biosynthesis in plants. His laboratory addresses fundamental questions about how lignin and related compounds are synthesized and incorporated into cell walls, how regulatory networks govern metabolic activity, and how lignification influences cell wall structure and function. A central aim of his research is optimizing plant feedstocks for efficient lignocellulosic biomass utilization. Analysis of Dr. Liu's publication record reveals a consistent trajectory from fundamental biochemical mechanisms to applied bioenergy solutions. His recent work focuses on cytochrome b5 diversity, electron transfer mechanisms in phenolic biosynthesis, and metabolic engineering approaches to modify lignin composition. This research spans from evolutionary studies of lignin biosynthesis across plant lineages to practical applications in bioenergy crop improvement. Dr. Liu has received recognition for his contributions to science, including: Brookhaven National Laboratory Science and Technology Award (2018) Dr. Liu serves as Editorial Board Member for the Journal of Biological Chemistry (2020-present), PNAS Nexus (2024-present), and Plant Physiology Journal (2025-). He is Scientific Lead at the Joint BioEnergy Institute, Feedstocks Division, Lawrence Berkeley National Laboratory, and Project Lead at the Center for Bioenergy Innovation, Oak Ridge National Laboratory. His research is funded by the U.S. Department of Energy through multiple Bioenergy Research Centers. Dr. Liu leads a research group at Brookhaven National Laboratory focused on elucidating the posttranslational regulation and macromolecular organization of lignin biosynthesis, with applications toward developing designer lignins and reducing biomass recalcitrance for sustainable biofuel production. His work addresses the critical challenge of lignin's dual nature: while it impedes enzymatic access to polysaccharides in biofuel production, it also represents the most abundant renewable source of aromatic carbon for high-value bioproducts.